Gut Microbiome Features of Chinese Patients Newly Diagnosed with Alzheimer's Disease or Mild Cognitive ImpairmentOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiome composition of patients newly diagnosed with Alzheimer's disease (AD) or mild cognitive impairment (MCI), before any medications or interventions were started. Researchers used 16S ribosomal RNA sequencing of fecal samples to characterize microbial community structure and compare it across diagnostic groups. The goal was to determine whether gut microbiome alterations were present at diagnosis and whether these alterations were more severe in AD than in MCI.
Who was studied?
The study included 18 patients newly diagnosed with AD, 20 patients newly diagnosed with MCI, and 18 age-matched healthy controls. Fecal samples were collected in the morning from all participants. None of the AD or MCI patients had received medications or other interventions for their condition before sample collection, distinguishing this cohort from prior studies of already-treated patients.
What were the most important findings?
Microbial alpha-diversity did not differ among the AD, MCI, and healthy control groups, but both AD and MCI patients showed increased beta-diversity compared with healthy controls. At the genus level, AD patients had decreased Bacteroides, Lachnospira, and Ruminiclostridium_9 along with increased Prevotella relative to healthy controls. MCI patients showed the same direction of change in these genera as AD patients, suggesting overlapping microbial alterations across the two conditions.
What are the greatest implications of this study?
Because these findings were observed in newly diagnosed, medication-naive patients, they suggest gut microbiome alterations may be present early in cognitive decline rather than resulting from treatment. The similarity in genus-level shifts between MCI and AD patients raises the possibility that microbiome changes track with the progression from mild impairment toward dementia. These results support further investigation of the gut microbiome as an early biomarker or contributing factor in Alzheimer's disease and its prodromal stages.